Collegium Pharmaceutical Inc (COLL) 2017年年度报告「NASDAQ」.pdf

1、Table of Contents0 4 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934?For the year ended December 31,2017 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE AC

2、T OF 1934?For the transition period from to Commission File Number 001-37372Collegium Pharmaceutical,Inc.(Exact name of registrant as specified in its charter)Virginia(State or other jurisdiction ofincorporation or organization)03-0416362(I.R.S.EmployerIdentification Number)780 Dedham Street,Suite 8

3、00Canton,MA(Address of principal executive offices)02021(Zip Code)(781)713-3699(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of exchange on which registered:Common stock,par value$0.001 per share The NASDAQ Global

4、 Select Market Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 o

5、r Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for suchshorter period that the registrant was required to file such reports),an

6、d(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website,if any,every Interactive Data File required to be submitted and posted pursuant to Rule405 of Regulation S-T(232